Replies to post #764275 on NorthWest Biotherapeutics Inc (NWBO)

[XMaster2023]

Hopefully, you simply fad to black now!

[SkyLimit2022]

Gabagool,

Thanks for posting your free pearls of wisdom 😶



Researching a company involves market research and forecasting the potential of the company’s entire asset portfolio within that market prospectively and globally with respect to the historical aspects of that market and existing technologies that are relevant to the overall living ecosystem … But you pop up here out of nowhere like a Gabagool-in-the-box, completely missing the forest for the trees—commenting about yourself, about one platform, or one trial. Nobody who works professionally in equity research would approach it that way…

Furthermore, your posts are generally baseless and highly unreliable. You need full-context, reliable citations to support your arguments—especially when commenting on medical aspects, where you lack qualifications entirely.

Who counts as actually qualified? Here are a few examples that leave no doubt:

✅️ Dr. Liau who is a world-renowned physician and currently serving on the SAB at NWBO

✅️ Dr. Kalinski at Roswell Park in New York

✅️ The U.S. NIH and U.S. DoD who awarded continuing peer-reviewed grants

✅️ The independent JAMA peer reviewers

✅️ The independent Nature Comms peer reviewers

✅️ MHRA which awarded approval of the PIP, approval of the MIA, and continue to support the Specials Program

✅️ Dr. Ashkan who was just honored with an award from the U.K. government




“His work on brain cancer vaccines received the top presentation award by the British Neuro-Oncology Society in 2022 and promises to impact the care of patients with brain tumours worldwide.”

Consultant Neurosurgeon at @KingsCollegeNHS, Professor Keyoumars Ashkan, receives an MBE for services to neurosurgery.
 
In 2020, he removed patient Dagmar's brain tumour while she played her violin throughout the surgery. 👇pic.twitter.com/H2Z4LZic0h

— NHS London (@NHSEnglandLDN) December 31, 2024

https://thejns.org/caselessons/view/journals/j-neurosurg-case-lessons/8/2/article-CASE24112.xml

https://www.kcl.ac.uk/news/professor-keyoumars-ashkan-awarded-mbe-in-kings-new-years-honours

Grant-funded trials are peer-reviewed, and the reviewers generally approve funding/expansion based on preliminary data. Notably, the PII trials at Roswell Park have been approved to expand in scope.. and look who joked on X about the overly-rigorous peer-review process for grant funding—the principal investigator of one of the Roswell trials!

Reviewers asking for prelim data when the grant mechanism says “prelim data not required” pic.twitter.com/qrBBnIvedt

— Sheheryar Kabraji (@SKabrajiMD) March 5, 2025

So, it looks like the grant peer reviewers have been watching the PII trials closely ✅️

The long-committed NWBO leadership team have built a comprehensive worldwide IP patent portfolio, acquired commercial licenses, acquired a novel patent-fortified technology to develop in-house automated manufacturing infrastructure, and trials are already underway with the continuing support of peer-reviewed U.S. government grants.

Both DCVax-L and the Roswell DC technology are being studied in combination with checkpoint inhibitors (and other agents). As efficacy data emerge and further studies commence, big pharma will increasingly view NWBO’s DC platforms as either a complement to their portfolios or a competitor. The results of these combination studies will determine the path forward, as the drugs being paired with NWBO’s DC technologies are already commercialized in a vast and swiftly expanding worldwide immunotherapy market.

Leveraging partnerships with world-renowned research institutions, such as Roswell Park in New York, and peer-reviewed grants from U.S. government agencies, such as the NIH, is both efficient and crucial in supporting the validity of breakthrough science and building value.

The trial that just posted a quality control update on Feb 25, 2025 and is led by Dr. Puzanov as principal investigator is a quite noteworthy example.

https://clinicaltrials.gov/study/NCT04093323






https://physicianresources.roswellpark.org/news/roswell-park-clinical-trials-offer-novel-immunotherapies-for-advanced/metastatic-tumors-refractory-melanoma

NWBO owns three distinct patent-fortified DC product platforms that we currently know about:

1. DCVax-L
2. DCVax Direct
3. Roswell’s DC Platform

✅️ Additionally, we might consider the novel EDEN manufacturing technology, which NWBO acquired through its strategic acquisition of Flaskworks in 2020.

Is is also quite noteworthy that the term “tumor-agnostic” was used in reference to the Roswell DC product platform:



https://www.sec.gov/ix?doc=/Archives/edgar/data/1072379/000141057824001879/nwbo-20240930x10q.htm






https://cdmrp.health.mil/bcrp/pbks/2024BCRPProgramBook.pdf

https://clinicaltrials.gov/study/NCT04348747

June 2024

https://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-exclusive-in-license-of-portfolio-of-dendritic-cell-technology-and-intellectual-property-302174237.html

“The license includes 5 new patent families that were just filed in 2023 and hence have their full potential patent life ahead of them. The technologies include enhanced versions of dendritic cells (DCs) and DC based therapies, as well as conditioning regimens designed to enhance patient responses and approaches to reprogram the tumour microenvironment to boost immune therapies and help overcome resistance to checkpoint inhibitors.

The DC based therapies include versions with tumour antigens loaded into the DCs and versions for intra-tumoural administration without pre-loading of antigens. Phase 2 trials involving the licensed technologies for two different cancers opened for enrollment earlier this year and are currently under way, and a third phase 2 trial for a third cancer is pending. The trials are fully funded by grant funding and are being conducted as investigator led trials. The company does not anticipate having to provide any funding or undertake any operational role for these trials.

As previously reported, over time the company has been quietly in-licensing various technologies and IP from various institutions and entities which it believes can be valuable in building a leading franchise in dendritic cell therapies.

The portfolio in-licensed from Roswell Park is complementary to, and builds upon, a portfolio which the company exclusively licensed from another institution last year. Together, the two portfolios encompass more than 20 years of work by one of the foremost groups of dendritic cell experts, led by Dr. Kalinski.

The portfolio in-licensed last year includes the foundational technologies and IP, and positive early-stage clinical trial results, developed by the Kalinski group over 17 years before coming to Roswell. The portfolio in-licensed now includes the further work during the last 7 years at Roswell. Taken together, the company believes that the two portfolios comprise a whole that is greater than the sum of its parts and offer compelling synergies with the company’s own portfolio. The company plans to collaborate with Dr. Kalinski on the further clinical development of the combined technologies.”

⭐️ Combo is King! ⭐️

https://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-exclusive-in-license-of-portfolio-of-dendritic-cell-technology-and-intellectual-property-302174237.html

https://nwbio.com/audio-of-nwbio-2023-annual-shareholders-meeting/



“They called me Gabagool Research”



https://investorshub.advfn.com/boards/read_msg.aspx?message_id=176114523

[jesster64]

"So I expect I’ll be next writing about them post approval"
I'm sure those that listened to your advice to sell will be waiting for your article.
maybe you can upgrade them to hold status then.
"post approval", not "post decision"?

[improving]

DelveInsight's report anticipates DCVax will be the largest revenue generating treatment for high grade GBM.

I'll stick with authors and researchers who are willing to put their names their work. Seems to work out better that way.

https://www.openpr.com/news/3671194/high-grade-glioma-market-2034-epidemiology-trends